# Abbott India (NSE: ABBOTINDIA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ABBOTINDIA · Pivot · prices to 21 Oct 2026

Abbott India (NSE: ABBOTINDIA) closed at ₹25,780.00 on 21 Oct 2026. With a market capitalisation of ₹55,705 Cr, it ranks 172nd by market cap among the 3,928 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 33.4% in FY25. Its 52-week range is ₹25,135.00 (11 Sep 2026) to ₹30,655.00 (25 Nov 2025); the last close is 15.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1,710 Cr (+6.5% year on year) and net profit ₹395 Cr (+7.6%), on a standalone basis. Promoters held 74.99% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹25,780.00 |
| Market cap | ₹55,705 Cr |
| ROE | 33.4% (FY25) |
| ROCE | 42.1% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹30,655.00 (25 Nov 2025) |
| 52-week low | ₹25,135.00 (11 Sep 2026) |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹1,710 Cr | +6.5% | ₹395 Cr | +7.6% | ₹185.85 |
| Q3 FY26 | ₹1,724 Cr | +6.8% | ₹376 Cr | +4.2% | ₹176.92 |
| Q2 FY26 | ₹1,757 Cr | +7.6% | ₹415 Cr | +15.8% | ₹195.42 |
| Q1 FY26 | ₹1,738 Cr | +11.6% | ₹366 Cr | +11.5% | ₹172.17 |
| Q4 FY25 | ₹1,605 Cr | +11.5% | ₹367 Cr | +27.9% | ₹172.72 |
| Q3 FY25 | ₹1,614 Cr | +12.3% | ₹361 Cr | +16.0% | ₹169.78 |
| Q2 FY25 | ₹1,633 Cr | +9.3% | ₹359 Cr | +14.6% | ₹168.76 |
| Q1 FY25 | ₹1,558 Cr | +5.3% | ₹328 Cr | +13.0% | ₹154.36 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹6,409 Cr | ₹1,414 Cr |
| FY24 | ₹5,849 Cr | ₹1,201 Cr |
| FY23 | ₹5,349 Cr | ₹949 Cr |
| FY22 | ₹4,919 Cr | ₹799 Cr |
| FY21 | ₹4,310 Cr | ₹691 Cr |
| FY20 | ₹4,093 Cr | ₹593 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 74.99%
- Foreign institutions: 0.38%
- Domestic institutions: 8.78%
- Non-institutions: 15.85%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | — | ₹67,290 Cr | — | — |
| [Alkem Laboratories](https://app.pivotnow.in/stock/ALKEM) | — | ₹64,248 Cr | — | — |
| [Glenmark Pharmaceuticals](https://app.pivotnow.in/stock/GLENMARK) | — | ₹62,467 Cr | — | — |
| [Anthem Biosciences](https://app.pivotnow.in/stock/ANTHEM) | — | ₹44,434 Cr | — | — |
| [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | — | ₹41,841 Cr | — | — |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | — | ₹40,232 Cr | — | — |

## Questions and answers

### What is the share price of Abbott India today?

Abbott India (NSE: ABBOTINDIA) last closed at ₹25,780.00 on 21 Oct 2026. Its 52-week high is ₹30,655.00 and its 52-week low is ₹25,135.00.

### What is the market cap of Abbott India?

Abbott India's market capitalisation is ₹55,705 Cr (₹55,705 Cr) at the — close, ranking 172nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Abbott India?

Return on equity was 33.4% in FY25 and return on capital employed was 42.1% in FY25 (standalone figures).

### Is Abbott India a debt-free company?

Abbott India is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Abbott India's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Abbott India reported revenue of ₹1,710 Cr, +6.5% year on year, and net profit of ₹395 Cr, +7.6% year on year.

### What is the shareholding pattern of Abbott India?

As of 30 Jun 2026: promoters 74.99%, foreign institutions 0.38%, domestic institutions 8.78%, non-institutions 15.85%.

### Who are Abbott India's competitors?

The listed Pharma & Healthcare companies closest to Abbott India by market cap are Biocon, Alkem Laboratories, Glenmark Pharmaceuticals, Anthem Biosciences, Aster DM Health and IPCA Laboratories.

### Is Abbott India a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Abbott India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ABBOTINDIA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.